Market watchers may have found it strange that CV Therapeutics traded up following Tuesday's bearish FDA panel meeting on CVTX's Ranexa ranolazine to treat chronic angina. But the stock had fallen below cash on Monday,...

Cancer company Xanthus (Cambridge, Mass.) raised $30.8 million in a series B round led by Oxford Bioscience. Other investors included CDP Capital - Technology Ventures; Hambrecht & Quist; GIMV; Genechem; China Development Industrial Bank; CDIB BioScience...

Chronogen (Montreal, Quebec), a developer of therapeutics for age-related degenerative diseases, raised C$17 million in an initial closing of a series B round. The financing was led by Desjardins Venture Capital. Other investors included the...

Avalon Pharmaceuticals Inc. Germantown, Md. Technology: Expression profiling, chemistry and bioinformatics Disease focus: Cancer Clinical status: NA Founded: 1999 by Kenneth Carter, Alan Walton, Thomas Ried, Brad Lorimier, Thomas David, Meena Augustus, and Jeff Cossma...